Recent News
Read ArticleWe have spent decades teaching that a gout flare is a joint problem: a hot, swollen, painful joint that we treat with anti-inflammatory drugs and move on from (i.e., the treat to avoid symptoms strategy). The campaign title says it well — gout is more than flares. I would add that a flare is more than a joint problem.
Fibrosis-4 (FIB-4) Index for Liver Fibrosis is calculated from age, AST, ALT, Plts. Study of 174 RA, PsA, PsO pts on MTX find 11% w/ fibrosis (by elastography). FIB-4 AUC for fibrosis =0.68 (weak). Fibrosis was signif assoc w/ FIB-4 >1.62, DM, obesity, advanced steatosis https://t.co/GYrhs2U1s3
Dr. John Cush @RheumNow ( View Tweet)
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease.
Sponsored by Bristol Myers Squibb. https://t.co/eZQoVpZpO0
#CARTCellTherapy https://t.co/SeBZFdFisi
Dr. John Cush @RheumNow ( View Tweet)
The Hidden Cost of Gout
For many people, gout is viewed as an episodic disease: a painful flare, a short course of treatment, and then life returns to normal. However, as rheumatologists, we know that recurrent attacks can lead to joint damage and tophi if left untreated. https://t.co/BfZFBZ8YrU
Dr. John Cush @RheumNow ( View Tweet)
Primary biliary cholangitis is a chronic cholestatic disease characterized by autoimmune-mediated destruction of bile ducts, leading to fibrosis, cirrhosis, & liver failure. Ursodeoxycholic acid is 1st line Rx. New Rx include elafibranor & seladelpar (activates peroxisome https://t.co/tKloXvJYek
Dr. John Cush @RheumNow ( View Tweet)
UK primary care database (2000–21) gout study of new colchicine initiators (n 31,478) vs noninitiators (mean 60 yrs, BMI 30), follow-up of 4.5 yrs. Colchicine use had a signif. 12% lower risk of Joint Arthroplasty (HR 0.88); 23% lower TJA in knee/hip OA (HR 0.77) https://t.co/bT07lUYBB2
Dr. John Cush @RheumNow ( View Tweet)
"Gout, unlike any other disease, kills more rich men than poor, more wise men than simple." — Thomas Sydenham
Dr. John Cush @RheumNow ( View Tweet)
GI dz & malnutrition in scleroderma (SSc) is common, assessed by BMI. Among 450 SSc (F/U 5.3 yrs), lower BMI were significantly assoc w/ pseudoobstruction, smaller oral aperture, higher Medsger vascular severity scores. Defines those at risk https://t.co/JY9YFOWE5C https://t.co/xFZ0rCXjQv
Dr. John Cush @RheumNow ( View Tweet)
Gout and its' associated comorbidities - treat gout and its' comorbidities to target
Created by : @Rheumat_aravind
https://t.co/AKT3rAvDBH https://t.co/SM248IPadR
Dr. John Cush @RheumNow ( View Tweet)
RheumIQ: True or False: Severe allergic reactions to allopurinol are more common in patients with chronic kidney disease than in the general population.
See if you got it right at https://t.co/LATb1P18Sh. https://t.co/dFdrhso1oU
Dr. John Cush @RheumNow ( View Tweet)
Persistence of education and monitoring is crucial to optimal gout management
Optimal gout care is dependent on having a well-informed health care provider who recognizes and follows the ACR gout management recommendations. It is important that the misconceptions and myths held https://t.co/XYSwvuihjJ
Dr. John Cush @RheumNow ( View Tweet)
Patients with anemia (10% of the population) have a 2-fold increased risk of gout.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/s8HeS9sbu0
Dr. John Cush @RheumNow ( View Tweet)
Expert Perspective on Calcium Pyrophosphate Deposition Disease
A current perspective article by Dr. Sara Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments. https://t.co/zxJ9aQweNl
Dr. John Cush @RheumNow ( View Tweet)
Chikungunya Club Meeting (7.24.2026)
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.
Read Article
Pragmatism in Gout: How therapeutic choices can have multiple benefits
William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. https://t.co/DG29pro6XE
Dr. John Cush @RheumNow ( View Tweet)
Gout and its' associated comorbidities - treat gout and its' comorbidities to target
https://t.co/U0dolcAGEc https://t.co/mGvYQrWx25
Dr. John Cush @RheumNow ( View Tweet)
Among 784,091 pts in a UK acute MI registry, 715 (0.1%) had SLE. SLE pts were younger & more female. SLE w/ MI had signif higher adjusted all-cause mortality from 30 days (HR 1.62) to 5 years (HR 1.84), despite age & having less traditional cardiovascular comorbidities https://t.co/78oHVWTdTJ
Dr. John Cush @RheumNow ( View Tweet)
Nerandomilast (Jascayd) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug was approved for IPF & PPF by the FDA for US use in late 2025 https://t.co/scOuVb3aYy https://t.co/EcmpRhyWgu
Dr. John Cush @RheumNow ( View Tweet)
Coding: ICD-10 Code M45.7 describes ankylosing spondylitis of the lumbosacral region, a billable ICD-10-CM diagnosis code valid for FY2026. M45.7 became effective October 1, 2025 and belongs to the M45 parent category covering ankylosing spondylitis by anatomical site. https://t.co/jBmoD0CVps
Dr. John Cush @RheumNow ( View Tweet)
Chinese cohort of 209 AOSD pts identifed 49 (23%) w/ lung dz (by CXR), yet 69% were asymptomatic. Significcant risk factors for AOSD-LD were pleuritis, MAS (HR 2.62), & Dz relapse (HR 2.6). Imaging patterns: acute exudative pattern most prevalent, followed by interstitial and https://t.co/2IPJWRJicP
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Chikungunya Club Meeting (7.24.2026)
Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.)-
Seronegative RA Disease Activity (7.17.202)
-
What Lies Beneath - Uric Acid Deposition & Imaging
Therapeutic Updates
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease
Read Post
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Check out our videos including: Genome-Wide Association Studies in Gout, Gout and Cardiovascular Disease and Gout & Obesity.
Read Post
Poster Hall
Daily Gem
Gout, unlike any other disease, kills more rich men than poor, more wise men than simple.
-- Thomas Sydenham